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A new, highly sensitive and specific enzyme immunoassay using oligopeptides as antigen (enzyme-linked
immunosorbent assay [ELISA] B19-OP) for detecting parvovirus B19-specific immunoglobulin G (IgG) was
established. As antigens, B19-specific oligopeptides of 24 and 30 kDa derived from a 196-kDa fusion protein of
I-galactosidase and viral capsid protein (VP1) of B19 after CNBr cleavage and separation by high-pressure
liquid chromatography were used. Of 139 serum specimens tested in parallel for anti-B19 IgG by standard
ELISA using B19 particles as antigen and by ELISA B19-OP, 73 (52.5%) were positive and 63 (45.3%) were
negative in both tests, and 3 (2.2%) were negative by standard ELISA but positive by ELISA B19-OP and by
immunoblot. By using ELISA B19-OP, it was possible to detect anti-B19 IgG in an asymptomatic blood donor
4 weeks after acute infection, and anti-B19 IgG titers of 10-5 could be measured in convalescent-phase sera.
The human parvovirus B19, first discovered by Cossart et
al. in 1975 (9), causes erythema infectiosum (3). In patients
with chronic hemolytic anemia, B19 infection can cause
aplastic crisis (4), and in pregnancy, B19 infection can lead
to hydrops fetalis resulting in fetal loss (6, 18). Recently, it
has been shown that chronic B19 infection can occur in
immunodeficient patients (14). Transmission of B19 by clot-
ting-factor concentrates in hemophilic patients has been
reported (5, 16), although the clinical features of such
infections have not been thoroughly investigated. B19 infec-
tion can also be associated with vascular purpura (15).
Until now, the serological diagnosis of acute or past B19
infection has been based on the detection of specific immu-
noglobulin M (IgM) or IgG by using viral particles partially
purified from plasma obtained from patients during the
viremic phase of B19 infection as antigen (1, 2, 8, 17). The
scarcity of B19 antigen-positive plasma limited the possibil-
ities of B19 antibody testing, and attempts to grow B19 in
permanent cell cultures have been unsuccessful. Recently,
B19 DNA was transfected into the genome of a Chinese
hamster ovary cell (CHO) line which then expressed B19
capsid proteins as noninfectious virionlike particles to be
used as antigen for serological assays (12). Also, the estab-
lishment of an enzyme-linked immunosorbent assay
(ELISA) for the detection of B19-specific IgM and IgG by
using a synthetic peptide has been recently reported (10).
The gene of the structural viral protein (VP1) of B19 had
been previously cloned into the expression vector pMLB
1115.216 and expressed in Escherichia coli, and thus a
196-kDa ,-galactosidase B19 fusion protein was obtained
which was reactive in immunoblot (20). However, until now,
problems with solubility have prevented its use for ELISAs.
In this paper, we describe the fragmentation of this B19
fusion protein by cyanbromide (CNBr) cleavage and the use
* Corresponding author.
t Present address: Department of Pediatrics, Institute of Clinical
Medicine, University of Tsukuba, Tsukuba-Shi, Japan.
of the resulting oligopeptides for detecting B19-specific IgG
by an oligopeptide enzyme immunoassay (ELISA B19-OP).
MATERIALS AND METHODS
Clinical specimens. A total of 139 serum specimens with
known B19 antibody status were tested. The 139 serum
specimens were as follows. (i) The first group of serum
specimens were acute-phase sera from an asymptomatic
blood donor (A; n = 8) and a patient with erythema infec-
tiosum (B; n = 15) collected 4, 6, 8, 12, 17, 19, 21, and 36
weeks after viremia (A) and up to 19 weeks after onset of
clinical disease (B). These 23 serum specimens (A and B)
were all anti-B19 IgG positive; up to week 19 (A) and week
14 (B), the sera were also IgM positive as determined by
ELISA (17). Except for sera from weeks 21 and 36, sera had
been titrated previously for anti-B19 IgG by ELISA (17),
and the titers were 10-3 (4 weeks), 10-5 (6 weeks), 10-5 (8
weeks), 10-6 (12 weeks), 10-6 (17 weeks), and 10-5 (19
weeks), with a prozone effect up to a dilution of 1:100 in all
sera taken after week 4 following viremia. (ii) The second
group of serum specimens included 50 that were positive for
anti-B19 IgG but negative for IgM by ELISA. (iii) The third
group included 59 serum specimens negative for anti-B19
IgM and IgG. (iv) The last group included sera (n = 7)
positive for rheumatoid factor by latex agglutination but
negative for anti-B19 IgG by ELISA (kindly supplied by B.
Wilske, Munich, Federal Republic of Germany). Addition-
ally, as random samples, sera of blood donors (n = 80) from
Chemnitz/GDR (kindly supplied by E. Gerike, Berlin, Ger-
man Democratic Republic) with unknown B19 antibody
status were tested to determine the cutoff of the ELISA
B19-OP.
Antigen preparation. The 196-kDa fusion protein of a-ga-
lactosidase and VP1 of parvovirus B19 truncated for 51
amino acids at the C terminus (20) was cleaved by the CNBr
method described by Gross and Witkop (11). According to
sequence data of P-galactosidase and VP1 of B19, 23 oli-
gopeptides of I-galactosidase (13) and 11 of VP1 (19) (Fig. 1)
should be generated after CNBr cleavage. For the cleavage
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FIG. 1. CNBr cleavage sites of all methionyl peptide bonds of the structural viral protein (VP1) of parvovirus B19 (19).
reaction, 1 ml of70% formic acid mixed with 0.1 mg ofCNBr
was added to 1 ml of the B19 fusion protein preparation (0.3
mg/ml in 6 M urea), vortexed, and incubated for 4 h at room
temperature. A 1-ml volume of H20 was then added. After
freeze-drying (Speed Vac Concentrator; Savant Instru-
ments, Farmingdale, N.Y.), the sample was dissolved in
about 4 ml of 1% trifluoroacetate and 6 M guanidine-
hydrochloride and was then fractionated by high-pressure
liquid chromatography (HPLC) by using a C4 wide-pore
reversed-phase column (Baker, Gross-Geran, Federal Re-
public of Germany). The flow rate was 2.0 ml/min when a
gradient of from 0 to 80% acetonitrile in 0.1% trifluoroace-
tate and H20 was used. Fifty fractions of 2 ml were
collected, freeze-dried in a speed-vac centrifuge, and resus-
pended in 150 ,ul of phosphate-buffered saline (PBS) plus 35
RI of 6 M guanidine.
Detection of B19-specific oligopeptides. To identify oli-
gopeptides of VP1 reacting with B19-specific IgG, the HPLC
fractions were diluted 1:100 in 0.2 M carbonate buffer, pH
9.5, and 50 IlI of each fraction was placed in duplicate wells
of flat-bottomed microtiter plates (Greiner, Nurtingen, Fed-
eral Republic of Germany) and incubated overnight in a wet
chamber at 4°C. After washing three times with PBS con-
taining 0.5% Tween-20 (washing buffer), 50 ,ul of an anti-B19
IgG-positive but IgM-negative serum or an anti-B19 IgG- and
IgM- negative serum (dilution of 1:100 in PBS containing 2%
Tween-20 and 3% fetal calf serum [PBS-TF]) was added to
each well and the wells were incubated for 2 h at 37°C in a
wet chamber. The wells were washed three times, 50 5.I of a
peroxidase-conjugated anti-human IgG (Dako, Copenhagen,
Denmark), diluted 1:1,000 in PBS-TF, was added, and the
wells were then incubated for 1 h at 37°C. Finally, plates
were washed three times, aspirated to dryness, and incu-
bated with 100 ,u of ortho-phenylenediamine (10 mg/ml) and
H202 (1 ,ul/ml) diluted in 0.2 M phosphate buffer, pH 6.0, for
15 min at 4°C in the dark. The reaction was stopped with 100
,1u of 1 M H2SO4, and the optical density (OD) was measured
in a multichannel photometer (SLT, Salzburg, Austria) at
492 nm.
Oligopeptide ELISA. For testing clinical specimens, the
ELISA B19-OP was performed as described above by using
dilutions (1:300) of fractions containing VP1 oligopeptides
reacting with anti-B19 IgG, a test serum dilution of 1:100,
and a dilution of peroxidase-conjugated anti-human IgG of
1:1,000. As controls, two anti-B19 IgG-positive and IgM-
negative and two anti-B19 IgG-negative and IgM-negative
serum specimens were tested in duplicate in each microtiter
plate. Test results were considered valid if the mean OD of
the positive control serum specimens was .0.700 and if the
mean OD of the negative control serum specimens was
<0.160. Sera were regarded as positive for anti-B19 IgG if
the mean OD of the test samples (S) was >2.1 the mean OD
of the negative control (N).
ELISA. As a reference test, standard ELISAs based on
the anti-y or anti-,u capture assay technique were used as
described previously (17). In brief, microtiter plates were
coated with anti--y or anti-,u and incubated with the test
serum. After incubation with B19 particles derived from
plasma of a blood donor, an anti-B19 monoclonal mouse
antibody and a peroxidase-conjugated anti-mouse IgG were
added.
Immunoblot. For determining anti-B19 IgG in sera, an
immunoblot was performed as described previously (17) by
using B19 antigen derived from a blood donor plasma. B19
viral proteins were transferred to nitrocellulose and incu-
bated with test sera and peroxidase-conjugated anti-human
IgG.
Oligopeptides of VP1 reacting with anti-B19 IgG were
analyzed by immunoblot by a previously described tech-
nique (17). After electrophoresis on a 20% sodium dodecyl
sulfate (SDS)-polyacrylamide gel, the oligopeptides were
transferred to nitrocellulose, incubated first with a serum
known positive for anti-B19 IgG but negative for IgM, and
then incubated with peroxidase-conjugated anti-human IgG.
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FIG. 2. Determination of B19-specific oligopeptides by enzyme
immunoassay after CNBr cleavage of a recombinant P-galactosidase
B19 fusion protein and separation by HPLC with an acetonitrile
gradient. The sera used are anti-B19 IgG positive and IgM negative
(0) and B19 IgG negative and IgM negative (0). Additionally, an
immunoblot of fraction 10 is shown.
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FIG. 3. Titration of sera taken consecutively from an asymptomatic patient (A) 4, 6, 8, 12, 17, 19, 21, and 36 weeks after donation of a
B19-positive blood unit and a serum specimen negative for B19 marker N (0) tested by ELISA B19-OP.
RESULTS
Separation of oligopeptides. The HPLC fractions (Fig. 2)
were analyzed in an ELISA for the B19 VP1 oligopeptides
by using anti-B19 IgG-positive and IgG-negative sera. Frac-
tions 9 to 11 reacted most strongly with anti-B19 IgG-
positive serum but not with anti-B19 IgG-negative serum,
indicating the presence of immunoreactive B19 oligopeptides
in these fractions. Fractions 9 to 11 were titrated in an
ELISA by using an S/N ratio of >2.1 with a standard
positive control serum as an endpoint. The titers were 10-2
for fraction 9, 1i-0 for fraction 10, and 10-2 for fraction 11.
Fraction 10 was used, therefore, for further evaluation of the
anti-B19 IgG test. Immunoblot analysis of fraction 10 re-
vealed two B19-specific proteins of 24 and 30 kDa which
reacted with an anti-B19 IgG-positive serum (Fig. 2).
Evaluation of the ELISA B19-OP. Different panels of sera
were tested by ELISA B19-OP to evaluate sensitivity and
specificity of the assay.
Sensitivity. Serum specimens (n = 8) taken consecutively
at 4, 6, 8, 12, 17, 19, 21, and 36 weeks after B19 viremia in a
blood donor (A) were titrated in log1o steps (Fig. 3). Sera in
a dilution corresponding to the same dilution of a negative
control serum were regarded as positive by ELISA B19-OP
if the S/N ratio was .2.1. The ELISA B19-OP identified all
eight serum specimens as anti-B19 IgG positive, with titers
ranging from 10-3 (4 weeks) to 10-5 (12 to 36 weeks). A
prozone effect, as observed in a previous titration of these
sera by standard ELISA, was not observed by the ELISA
B19-OP (17). For further testing, a serum dilution of 1:100
was chosen. Sera (n = 15) taken consecutively from another
patient (B) up to 19 weeks after onset of clinical disease were
all positive for anti-B19 IgG in a serum dilution of 1:100, and
titration yielded titers of 10- to 10-5.
Sera (n = 50) positive for anti-B19 IgG but negative for
IgM by ELISA (dilution 1:100) from the diagnostic virology
laboratories of the Max von Pettenkofer Institute were also
anti-B19 IgG positive by ELISA B19-OP.
Specificity. To examine the possibility that false-positive
reactions could be caused by rheumatoid factor, seven
serum specimens positive for rheumatoid factor but negative
for anti-B19 IgG by standard ELISA were tested by ELISA
B19-OP; all were clearly negative. Sera (n = 59) which were
anti-B19 IgG and IgM negative by standard ELISA were
tested by ELISA B19-OP; 56 (94.9%) were negative and 3
(5.1%) were positive by ELISA B19-OP. These three sera
(negative by standard ELISA but positive by ELISA
B19-OP with an S/N ratio between 2.1 and 3.0) were positive
for anti-B19 IgG by immunoblot analysis reacting against the
major structural protein VP2. No antibodies were detected
against VP1.
In total, results of all sera (n = 139), both anti-B19 IgG
positive and negative, of 115 individuals tested previously by
standard ELISA (17) were in agreement with results from
ELISA B19-OP in 136 serum specimens (97.8%); 3 serum
specimens (2.2%) of three individuals which were negative
by standard ELISA were positive by ELISA B19-OP.
Reproducibility. For determining the reproducibility of
ELISA B19-OP, one negative control serum specimen and
two positive control serum specimens were tested repeat-
edly in eight assays of the same batch of VP1 oligopeptides
in duplicate over 5 days. The OD variation of the negative
control serum ranged from 0.110 to 0.165, and the two
positive control serum specimens consistently gave OD
values of >0.800. Only VP1 oligopeptide batches which
discriminated between these standard control sera in the OD
ranges mentioned above were used for testing.
Screening of blood donor. To investigate the OD distribu-
tion of a random sample, sera of blood donors (n = 80) with
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FIG. 4. Scattergram of the OD of sera (n = 80) of blood donors from Chemnitz/GDR, with unknown B19 immune status tested by ELISA
B19-OP (dilution 1:100).
unknown B19 antibody status from Chemnitz/GDR were
tested by ELISA B19-OP (Fig. 4). Of these 80 serum
specimens tested in one assay, 34 (42.5%) gave an OD value
of <0.18 (mean, 0.10), 34 (42.5%) gave an OD value of
>0.55, and 12 (15.0%) gave an OD value of 0.21 to 0.40. Five
serum specimens of the later group (OD of 0.21 to 0.40) were
tested by immunoblot, and all five were positive for anti-B19
IgG reacting with VP2. An S/N ratio of >2.1 was therefore
taken as cutoff between anti-B19 IgG-positive and -negative
sera. Nevertheless, sera in the gray zone with an S/N ratio of
2.1 to 4.0 were regarded as borderline.
DISCUSSION
By CNBr cleavage (11) of the fusion protein and HPLC
fractionation of the oligopeptides, we were able to eliminate
previous problems with the solubility of a 3-galactosidase
VP1 B19 fusion protein so that some fractions could be used
as an antigen for an enzyme immunoassay (ELISA B19-OP).
As shown by immunoblot (Fig. 2), the oligopeptides reactive
with B19-specific IgG in the ELISA B19-OP are two proteins
of 24 and 30 kDa. Only one oligopeptide of that size (24 kDa)
is located at the amino-terminal end at positions 1 to 228,
according to the amino acid sequence of B19 VP1. We think
there may be an incomplete cleavage at the methionine at
position 251, resulting in the additional, larger oligopeptide
of 30 kDa. As both oligopeptides were reactive in immuno-
blot, it is likely that an immunogenic region for the detection
of anti-B19 IgG is located in amino acid positions 1 to 228.
It has been published recently that a synthetic peptide of
the amino acids at positions 284 to 307 can be used as antigen
for detecting anti-B19 IgM and IgG (10). This sequence is
localized in the VP2 region. According to the immunoblot
analysis, the oligopeptide which we use as antigen for the
detection of anti-B19 IgG is localized in the VP1 region.
By using CNBr cleavage and HPLC fractionation of the
1-galactosidase VP1 B19 fusion protein, we also tried to
obtain VP1 oligopeptides reacting with anti-B19 IgM to
establish an IgM test. However, the results obtained so far
were inconsistent. Evaluation of the ELISA B19-OP showed
that it is highly sensitive and specific for detecting anti-B19
IgG. Sera with known anti-B19 IgG titer by standard ELISA
were also found positive with comparable titers by ELISA
B19-OP. In addition, anti-B19 IgG could be detected by
ELISA B19-OP in three serum specimens negative by stan-
dard ELISA, and the anti-B19 IgG positivity of these three
serum specimens was confirmed by immunoblot. In using
oligopeptides as antigen, it is possible that antibodies di-
rected against the same epitopes present on whole virions
are not detected. At present, it is not known whether this
causes false-negative results.
With ELISA B19-OP, anti-B19 IgG could be detected in a
serum specimen of a patient taken 1 week after onset of
erythema infectiosum and 4 weeks after viremia occurred in
a blood donor. This early detection of anti-B19 IgG is the
same as that of previous observations by using standard
ELISA or radioimmunoassay (1, 6, 8, 17). All convalescent-
phase sera were anti-B19 IgG positive by ELISA B19-OP.
The OD distribution of a random sample of sera of blood
donors (n = 80) showed that an S/N ratio of >5.0 can be
determined in 34 serum specimens (42.5%). These sera can
be regarded as positive. Thirty-four (42.5%) serum speci-
mens gave an S/N ratio of <2.1 and can be regarded as
negative. In 12 (15.0%) serum specimens, the S/N ratio was
between 2.1 and 4.0. These sera should be regarded as
borderline and retested in another test system to confirm the
reactivity. Immunoblot analysis with B19 virus or recombi-
nant B19 viral proteins as antigen should be performed in
sera with borderline S/N ratios. However, as immunoblot
analysis lacks sensitivity, false-negative results are still
possible. Further studies are necessary to clearly define the
cutoff value of the ELISA B19-OP. Positive and negative
results of specimens in the assay were reproducible. How-
ever, as differences in the oligopeptide batches related to
purification of crude P-galactosidase VP1 B19 fusion protein
and to separation by HPLC were observed, only batches
which discriminated between the negative and the positive
control sera in the OD ranges mentioned above were used
for testing.
Test systems for detecting anti-B19 IgG are still not widely
available because of insufficient supplies of B19 virus (1, 2,
8, 17). Use of infectious B19 particles for antibody tests has
led to several infections of laboratory staff (7); use of ELISA
B19-OP avoids such handling of infectious materials.
In comparison with the standard ELISA and radioimmu-
noassay (1, 2, 8, 17), by using B19 particles and requiring an
overnight step, the ELISA B19-OP demands little time (3.5
h) and makes possible rapid analysis of the B19 immune
status. This can be clinically important in cases of contact
with B19 in pregnant women, as those who are anti-B19 IgG
positive at contact have no risk of infection.
With the B19 oligopeptide enzyme immunoassay (ELISA
B19-OP), a test system has been established which can be
used widely for anti-B19 IgG screening.
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